52 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B N/A
Article Searches
Top Research Reports for Facebook, McDonalds & Bristol-Myers http://www.zacks.com/research-daily/1057239/top-research-reports-for-facebook-mcdonalds-bristol-myers?cid=CS-ZC-FT-research_daily-1057239 Sep 11, 2020 - Top Research Reports for Facebook, McDonalds & Bristol-Myers
AVEO's NDA for Fotivda on Track, FDA Verdict Due Next Year http://www.zacks.com/stock/news/1055169/aveos-nda-for-fotivda-on-track-fda-verdict-due-next-year?cid=CS-ZC-FT-analyst_blog|zer_report_update-1055169 Sep 08, 2020 - AVEO Pharmaceuticals (AVEO) seeks an FDA nod for Fotivda in the United States to treat relapsed or refractory RCC. A decision from the regulatory agency is expected on Mar 31, 2021.
Benzinga Pro's Top 5 Stocks To Watch For Mon., May 4, 2020: DIS, BMY, PTON, QTNT, TBIO http://feeds.benzinga.com/~r/benzinga/~3/nPa4-eZXTeM/benzinga-pros-top-5-stocks-to-watch-for-mon-may-4-2020-dis-bmy-pton-qtnt-tbio May 04, 2020 -

Today's 5 Stock Ideas: 

Disney (DIS) - An earnings play. Will report quarterly results after the close on Tuesday, May 5, 2020. 
Bristol Myers Squibb (BMY) - A play on upcoming data related to

read more

Amgen (AMGN) Q1 Earnings Top, to Study Otezla for Coronavirus http://www.zacks.com/stock/news/910436/amgen-amgn-q1-earnings-top-to-study-otezla-for-coronavirus?cid=CS-ZC-FT-analyst_blog|earnings_article-910436 May 01, 2020 - Amgen (AMGN) beats estimates for both earnings and sales. It maintains its previously-issued financial guidance for 2020.
Agios' (AGIO) Q1 Loss Narrower Than Expected, Revenues Beat http://www.zacks.com/stock/news/910298/agios-agio-q1-loss-narrower-than-expected-revenues-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-910298 May 01, 2020 - Agios' (AGIO) loss and revenues better estimates in Q1. The company's wholly owned leukemia drug Tibsovo sees a sequential rise in sales.
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth http://www.zacks.com/stock/news/901853/bristol-myers-squibb-bmy-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-901853 Apr 30, 2020 - Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Forget Dividend Cuts, Here Are 5 Solid Growth Picks for You http://www.zacks.com/stock/news/897391/forget-dividend-cuts-here-are-5-solid-growth-picks-for-you?cid=CS-ZC-FT-analyst_blog|rw-897391 Apr 29, 2020 - Against the backdrop of near-zero interest environment and a series of drastic dividend cuts, investors are zeroing in on stocks that not only offer dividends but also consistently increase their payout.
3 Bargain Stocks You Can Buy Right Now https://www.fool.com/investing/2020/04/26/3-bargain-stocks-you-can-buy-right-now.aspx?source=iedfolrf0000001 Apr 26, 2020 - These stocks won't be available at the current discounts for too long.
Pharma Stock Roundup: Q1 Earnings of LLY, Coronavirus Update from PFE, NVS, AZN http://www.zacks.com/stock/news/887364/pharma-stock-roundup-q1-earnings-of-lly-coronavirus-update-from-pfe-nvs-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-887364 Apr 24, 2020 - Eli Lilly (LLY) announces Q1 results. Pfizer (PFE) and Novartis (NVS) provide update on their studies/plans to make coronavirus treatments or vaccines.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase? http://www.zacks.com/stock/news/887532/will-pfizers-pfe-biopharma-unit-q1-earnings-increase?cid=CS-ZC-FT-analyst_blog|earnings_preview-887532 Apr 24, 2020 - In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.

Pages: 123456

Page 1>